Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Increlex

PreclinicalSmall molecule

EEsteve Pharmaceuticals, S.A.

Increlex is one of 95 small molecule programs targeting Growth. It is currently in Preclinical.

2

Indications

5

Total Trials

1

Active Trials

94

Competitors

Pipeline

Status by Indication[3][1]

Indication

GrowthActive, not recruiting

Liver DiseaseActive, not recruiting

GrowthPreclinical

Active, not recruiting

Liver DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

100 competitors in Liver Disease

#DrugCompanyPhaseTrials

Dayvigo

Cibinqo

Balversa

Johnson & Johnson

Piqray

Kalydeco

Vertex Pharmaceuticals

Sovaldi

Myrbetriq

Eloxatin

Zykadia

Actigall

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Growth

NCT00903110

Clinical

Trials by Indication[1]

Short stature1 trial

IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency

Completed·—·Phase 1/2·NCT02636270·7 enrolled

Growth1 trial

Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Recruiting·EEsteve Pharmaceuticals, S.A.··NCT00903110·500 enrolled

Liver Disease1 trial

Increlex Treatment of Children With Chronic Liver Disease and Short Stature

Withdrawn·UUniversity of California, Los Angeles·N/A·NCT01314508

Severe Combined Immunodeficiency1 trial

Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00490100·6 enrolled

Concentration1 trial

IGF-I Induced Muscle Glucose Uptake and Interstitial IGF-I Concentrations

Completed·PPeter Bang·N/A·NCT01588093·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Increlex. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Increlex compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Increlex. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Esteve Pharmaceuticals, S.A. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: EEsteve Pharmaceuticals, S.A.

Related News